

PRISTINE BIOLOGICALS (NZ) LIMITED

(A wholly owned subsidiary of Indian Immunologicals Limited)

Statement of Financial Performance			
For the year ended 31 st March 2026			(Amt in NZD)
S.No.	PARTICULARS	Year 2026	Year 2025
1.	Total Sales	4,734,814	5,397,382
2.	Cost of sales	2,697,129	3,166,274
	Gross Surplus	2,037,684	2,231,108
4.	Add: Other Income	343	14
5.	Less: Expenses	1,081,719	1,034,767
	Net surplus/(deficit) before depreciation	956,280	1,197,905
6.	Less : Other adjustments (Depreciation/Foreign currency loss/other Taxation)	273,282	338,861
	NET SURPLUS/(DEFICIT)	682,998	859,044

Statement of Financial Position			
As at 31 st March 2026			(Amt in NZD)
S.No.	PARTICULARS	Year 2026	Year 2025
1.	Current Assets	3,217,467	2,897,768
2.	Non-Current Assets	1,599,230	1,714,466
	TOTAL ASSETS	4,816,697	4,612,235
3.	Current Liabilities	411,236	800,409
4.	Non-Current Liabilities	312,770	402,133
	TOTAL LIABILITIES	724,006	1,202,542
	NET ASSETS	4,092,691	3,409,693
	TOTAL EQUITY	4,092,691	3,409,693